Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting

Hypertension

Volumn 58, Issue 4, 2011, Pages 643-649

  Tabony, A Michael ^a   Yoshida, Tadashi ^a   Galvez, Sarah ^a   Higashi, Yusuke ^a   Sukhanov, Sergiy ^a   Chandrasekar, Bysani ^a   Mitch, William E ^b   Delafontaine, Patrice ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AICAR; Akt; AMPK; ATP; atrogin 1; mitochondria; muscle RING finger protein 1

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MUSCLE RING FINGER 1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPETITE; ARTICLE; CALORIC RESTRICTION; CONTROLLED STUDY; ENERGY BALANCE; ENZYME ACTIVITY; FOOD INTAKE; GASTROCNEMIUS MUSCLE; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; WEIGHT REDUCTION;

ADENOSINE TRIPHOSPHATE; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANGIOTENSIN II; ANIMALS; ENERGY METABOLISM; MALE; MICE; MICE, INBRED STRAINS; MITOCHONDRIA, MUSCLE; MODELS, ANIMAL; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PHOSPHOPROTEIN PHOSPHATASES; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UP-REGULATION;

EID: 80053519193     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.174839     Document Type: Article

References (40)

1. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology. 2001;142:1489-1496. (Pubitemid 32299677)
2. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressorindependent mechanism. J Clin Invest. 1996;97:2509-2516. (Pubitemid 26187338)
3. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Musclespecific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest. 2005;115:451-458. (Pubitemid 40385487)
4. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050-1053. (Pubitemid 27158249)
5. Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol. 2002;5: 188-199. (Pubitemid 35283512)
6. Du J, Hu Z, Mitch WE. Cellular signals activating muscle proteolysis in chronic kidney disease: a two-stage process. Int J Biochem Cell Biol. 2005;37:2147-2155. (Pubitemid 41206827)
7. Rajan V, Mitch WE. Ubiquitin, proteasomes and proteolytic mechanisms activated by kidney disease. Biochim Biophys Acta. 2008;1782:795-799.
8. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin ii inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest. 1997;100:2158-2169. (Pubitemid 27500137)
9. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes. 1999;107:133-139. (Pubitemid 29179280)
10. Workeneh BT, Mitch WE. Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr. 2010;91:1128S-1132S.
11. Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P. IGF-1 prevents Ang II-induced skeletal muscle atrophy via Akt-and FOXOdependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol. 2010;298:H1565-H1570.
12. Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, Mitch WE. Il-6 and serum amyloid a synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol. 2009;20:604-612.
13. Sato H, Watanabe A, Tanaka T, Koitabashi N, Arai M, Kurabayashi M, Yokoyama T. Regulation of the human tumor necrosis factor-αpromoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and transcriptional factors. J Mol Cell Cardiol. 2003;35:1197-1205. (Pubitemid 37163528)
14. Zera T, Ufnal M, Szczepanska-Sadowska E. Central TNF-αelevates blood pressure and sensitizes to central pressor action of angiotensin II in the infarcted rats. J Physiol Pharmacol. 2008;59(suppl 8):117-121.
15. Brink M, Anwar A, Delafontaine P. Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int J Cardiol. 2002;85:111-121, discussion 121-114.
16. Mitsuishi M, Miyashita K, Muraki A, Itoh H. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes. 2009;58:710-717.
17. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol. 2003;30:860-866. (Pubitemid 37506154)
18. Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P. IGF-1 prevents Ang II-induced skeletal muscle atrophy via akt-and foxodependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol. 2010;298:H1565-H1570.
19. Sanders MJ, Grondin PO, Hegarty BD, Snowden MA, Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J. 2007;403:139-148. (Pubitemid 46569875)
20. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D. Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of amp-activated protein kinase. J Biol Chem. 2006;281: 32207-32216. (Pubitemid 46036775)
21. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, Brunet A. The energy sensor AMP-activated protein kinase directly regulates the mammalian foxo3 transcription factor. J Biol Chem. 2007;282: 30107-30119. (Pubitemid 350035296)
22. Tong JF, Yan X, Zhu MJ, Du M. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in c2c12 myotubes. J Cell Biochem. 2009;108: 458-468.
23. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. Foxo3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007;6:472-483. (Pubitemid 350163056)
24. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med. 2008;14: 539-549.
25. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre P, Birnbaum MJ, Stuck BJ, Kahn BB. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569-574. (Pubitemid 38480541)
26. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, Pedersen O, Schmitz O, Lund S. Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes. 2002;51:2199-2206. (Pubitemid 34729025)
27. Reiter AK, Crozier SJ, Kimball SR, Jefferson LS. Meal feeding alters translational control of gene expression in rat liver. J Nutr. 2005;135: 367-375. (Pubitemid 40365190)
28. Wu MW, Li XM, Xian LJ, Levi F. Effects of meal timing on tumor progression in mice. Life Sci. 2004;75:1181-1193. (Pubitemid 38829343)
29. Culmsee C, Monnig J, Kemp BE, Mattson MP. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci. 2001;17:45-58. (Pubitemid 32928285)
30. Peralta C, Bartrons R, Serafin A, Blazquez C, Guzman M, Prats N, Xaus C, Cutillas B, Gelpi E, Rosello-Catafau J. Adenosine monophosphate-activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat. Hepatology. 2001;34:1164-1173. (Pubitemid 33096589)
31. Sukhodub A, Jovanovic S, Du Q, Budas G, Clelland AK, Shen M, Sakamoto K, Tian R, Jovanovic A. AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive k(+) channels. J Cell Physiol. 2007;210:224-236. (Pubitemid 44904718)
32. Steinberg GR, Michell BJ, Van Denderen BJ, Watt MJ, Carey AL, Fam BC, Andrikopoulos S, Proietto J, Gorgun CZ, Carling D, Hotamisligil GS, Febbraio MA, Kay TW, Kemp BE. Tumor necrosis factorα-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab. 2006;4:465-474. (Pubitemid 44834113)
33. Semprun-Prieto LC, Sukhanov S, Yoshida T, Rezk BM, Gonzalez-Villalobos RA, Vaughn C, Michael Tabony A, Delafontaine P. Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem Biophys Res Commun. 2011;409:217-221.
34. Irrcher I, Ljubicic V, Kirwan AF, Hood DA. AMP-activated protein kinase-regulated activation of the PGC-1αpromoter in skeletal muscle cells. PLoS One. 2008;3:e3614.
35. McGee SL, Hargreaves M. AMPK-mediated regulation of transcription in skeletal muscle. Clin Sci (Lond). 2010;118:507-518.
36. Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, Torri M, Anesini A, Salio M, Pasotti E, Agnello D, Santoro L, Catania A, Ghezzi P, Moccetti T, Maggioni AP. Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res. 1998;37:213-217. (Pubitemid 28174854)
37. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin ii despite ace inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000;21:53-57. (Pubitemid 30042669)
38. Graziani G, Badalamenti S, Del Bo A, Marabini M, Gazzano G, Como G, Vigano E, Ambroso G, Morganti A. Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment. Kidney Int. 1993;44:107-114. (Pubitemid 23198032)
39. Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, Katsurada A, Tran DV, Kobori H, Navar LG. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol. 2008;295:F772-F779.
40. Ortiz RM, Kobori H, Conte D, Navar LG. Angiotensin II-induced reduction in body mass is Ang II receptor mediated in association with elevated corticosterone. Growth Horm IGF Res. 2010;20:282-288.